235 related articles for article (PubMed ID: 17886253)
1. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Carducci MA; Saad F; Abrahamsson PA; Dearnaley DP; Schulman CC; North SA; Sleep DJ; Isaacson JD; Nelson JB;
Cancer; 2007 Nov; 110(9):1959-66. PubMed ID: 17886253
[TBL] [Abstract][Full Text] [Related]
2. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Nelson JB; Love W; Chin JL; Saad F; Schulman CC; Sleep DJ; Qian J; Steinberg J; Carducci M;
Cancer; 2008 Nov; 113(9):2478-87. PubMed ID: 18785254
[TBL] [Abstract][Full Text] [Related]
3. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
5. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB; Nabulsi AA; Vogelzang NJ; Breul J; Zonnenberg BA; Daliani DD; Schulman CC; Carducci MA
J Urol; 2003 Mar; 169(3):1143-9. PubMed ID: 12576870
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Quinn DI; Tangen CM; Hussain M; Lara PN; Goldkorn A; Moinpour CM; Garzotto MG; Mack PC; Carducci MA; Monk JP; Twardowski PW; Van Veldhuizen PJ; Agarwal N; Higano CS; Vogelzang NJ; Thompson IM
Lancet Oncol; 2013 Aug; 14(9):893-900. PubMed ID: 23871417
[TBL] [Abstract][Full Text] [Related]
7. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Lara PN; Ely B; Quinn DI; Mack PC; Tangen C; Gertz E; Twardowski PW; Goldkorn A; Hussain M; Vogelzang NJ; Thompson IM; Van Loan MD
J Natl Cancer Inst; 2014 Apr; 106(4):dju013. PubMed ID: 24565955
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR
Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927
[TBL] [Abstract][Full Text] [Related]
9. Atrasentan for metastatic hormone refractory prostate cancer.
Murphy G
Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Zonnenberg BA; Groenewegen G; Janus TJ; Leahy TW; Humerickhouse RA; Isaacson JD; Carr RA; Voest E
Clin Cancer Res; 2003 Aug; 9(8):2965-72. PubMed ID: 12912943
[TBL] [Abstract][Full Text] [Related]
11. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
[TBL] [Abstract][Full Text] [Related]
12. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
13. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
[TBL] [Abstract][Full Text] [Related]
15. Bone-specific growth inhibition of prostate cancer metastasis by atrasentan.
Drake JM; Danke JR; Henry MD
Cancer Biol Ther; 2010 Apr; 9(8):607-14. PubMed ID: 20139704
[TBL] [Abstract][Full Text] [Related]
16. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Carducci MA; Nelson JB; Bowling MK; Rogers T; Eisenberger MA; Sinibaldi V; Donehower R; Leahy TL; Carr RA; Isaacson JD; Janus TJ; Andre A; Hosmane BS; Padley RJ
J Clin Oncol; 2002 Apr; 20(8):2171-80. PubMed ID: 11956279
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials of atrasentan in hormone-refractory prostate cancer.
Lee D
Clin Prostate Cancer; 2003 Sep; 2(2):84-6. PubMed ID: 15040868
[No Abstract] [Full Text] [Related]
18. Endothelin receptor antagonists in the treatment of prostate cancer.
Lassiter LK; Carducci MA
Semin Oncol; 2003 Oct; 30(5):678-88. PubMed ID: 14571415
[TBL] [Abstract][Full Text] [Related]
19. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Nelson JB; Fizazi K; Miller K; Higano C; Moul JW; Akaza H; Morris T; McIntosh S; Pemberton K; Gleave M
Cancer; 2012 Nov; 118(22):5709-18. PubMed ID: 22786751
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]